## Dosage and administration

### Nonvalvular atrial fibrillation

CrCl | Dose
--- | ---
>95 mL/min | DO NOT USE!
>50 to ≤95 mL/min | 60 mg PO once daily
≥15 to <50 mL/min | 30 mg PO once daily
<15 mL/min | DO NOT USE!

Note: Do not use with CrCl >95 mL/min!

### DVT and PE

CrCl | Dose
--- | ---
>50 mL/min | 60 mg orally once daily
≥15 to <50 mL/min | 30 mg orally once daily

Patients with body weight ≤60 kg or receiving certain P-gp inhibitors (verapamil, quinidine, azithromycin, clarithromycin, erythromycin, itraconazole or ketoconazole) use 30 mg once daily.

## Dosage forms and strengths

- Tablets
  - 15 mg
  - 30 mg
  - 60 mg

## Contraindications

- Active pathological bleeding

## Warnings and precautions

- Bleeding: serious and potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss.
- Mechanical heart valves or moderate to severe mitral stenosis: Use is not recommended.

## Adverse reactions

- Treatment of nonvalvular AF: The most common adverse reactions (≥5%) are bleeding and anemia.
- Treatment of DVT and PE: The most common adverse reactions (≥1%) are bleeding, rash, abnormal liver function tests and anemia.

## Drug interactions

- Anticoagulants: Avoid concomitant use.
- Rifampin: Avoid concomitant use.

## Use in specific populations

- Nursing mothers: Discontinue drug or discontinue nursing.
- Impaired renal function: Reduce dose (see tables above).
- Moderate or severe hepatic impairment: Not recommended.